MacroGenics to Participate in Upcoming Investor Conferences

Core Insights - MacroGenics, Inc. is a biopharmaceutical company focused on developing monoclonal antibody-based therapeutics for cancer treatment [3] - The company will participate in two upcoming investor conferences in November 2024, including the Guggenheim Securities Healthcare Innovation Conference and the Stifel 2024 Healthcare Conference [1] Conference Participation - At the Guggenheim Securities Healthcare Innovation Conference in Boston, the Chief Operating Officer, Eric Risser, will engage in a fireside chat on November 12, 2024, at 4:00 PM ET [1] - The President & CEO, Scott Koenig, M.D., Ph.D., will participate in a fireside chat at the Stifel 2024 Healthcare Conference in New York on November 18, 2024, at 1:15 PM ET [1] - Management will also hold one-on-one meetings at both conferences [1] Company Overview - MacroGenics generates its product pipeline from proprietary next-generation antibody-based technology platforms applicable across various therapeutic domains [3] - The company has established strategic collaborations with global pharmaceutical and biotechnology firms, leveraging its technology and protein engineering expertise [3]